An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
| Title: | An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) |
|---|---|
| Authors: | Grosicki, Sebastian, Iosava, Genadi *, Zodelava, Mamia *, Tzvetkov, Nikolay *, Robak, Tadeusz, Radinoff, Atanas *, Routhu, Kasi Viswanath *, Barde, Prajak *, Nair, Ajit Mohanchandran * |
| Source: | In Blood 5 November 2020 136 Supplement 1:25-25 |
| Database: | ScienceDirect |
| ISSN: | 00064971 |
|---|---|
| DOI: | 10.1182/blood-2020-136031 |
| Published in: | Blood |
| Language: | English |